Aspen Neuroscience files for $140.6 million Nasdaq IPO
Cell therapy developer Aspen Neuroscience plans a Nasdaq IPO of 9.375 million shares at $15, ticker ASPE, to fund Parkinson's trials.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Aspen Neuroscience has filed for an initial public offering on Nasdaq, according to TradingView, which cites documents filed with the SEC. The company plans to sell 9,375,000 shares at $15 each, for gross proceeds of about $140.6 million. If listed, the shares will trade on the Nasdaq Global Select Market under the symbol ASPE.
Most of the money is earmarked for clinical work on sasineprocel, its cell therapy candidate for Parkinson's disease, including a planned Phase 3 trial. The treatment is made from the patient's own induced pluripotent stem cells and is delivered to the brain by surgery. As of August 18, 2026, 15 patients had been treated in the ongoing Phase 1/2a study. The company has no product revenue so far, and its net loss for the six months ended June 30, 2026 was $36.5 million.
why it matters
For the broader market this is a routine offering from a small biotech with no product sales, so the main audience is sector investors. For the shares, the key factors will be clinical trial results and access to financing before any commercial product exists.
tags
instruments
sources
- Aspen Neuroscience, Autologous Cell Therapies for Neurological Disease, Files for Nasdaq IPO — TradingView, 30 October 2026 at 20:49 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗